Clinical Trials Market

Clinical Trials Market by Phase (Phase I, II, III), Service Type (Site Identification, Laboratory Services, Decentralized Clinical Trial), Therapy Area (Oncology, Infectious Disease), and Application (Vaccines, Cell & Gene Therapy) (2022 - 2026)

Report Code: PH 1622 Feb, 2022, by marketsandmarkets.com

[317 Pages Report] The clinical trials market is projected to reach USD 52.0 billion by 2026 from USD 38.7 billion in 2021, at a CAGR of 6.1% during the forecast period. High demand for decentralized clinical trial services amidst the COVID-19 pandemic is expected to provide momentum to the market. High investments in pharmaceutical R&D have led to a significant elevation in the number of clinical trials conducted in the past few years.

Clinical Trials Market

To know about the assumptions considered for the study, Request for Free Sample Report

Covid-19 Impact on the Global Clinical Trials Market

Several pharmaceutical and biotechnology companies have entered the race of vaccine development against the SARS-CoV-2 infection. The need of rapid commercialization of COVID-19 vaccines offers lucrative opportunities to the companies operating in this market space, thereby propelling them to explore outsourcing of clinical trial services. WHO has indicated that the number of vaccines for COVID-19 increased significantly after the third quarter of 2020. Presently 80 vaccines are in the clinical trial phase, which indicates high demand for COVID-19 vaccine trials in the coming years. Moreover, due to COVID-19, the demand for ready-to-plug-in infrastructure to expedite timelines of clinical trials amidst the restrictions imposed by the pandemic has increased.

The development of dedicated services for COVID-19 by clinical research entities is set to supplement the market growth further. Strategic partnerships and collaborations of pharmaceutical companies with academic institutes has helped in managing the COVID-19 effectively across the globe. This has further opened up new aveneues of market expansion small and large clinical research service providers. High investments to strengthen the manufacturing capabiltities aimed at achieving the required production of COVID-19 drugs/vaccines has proved as a catalyst clinical trials market.

Clinical Trails Market Dynamics

Driver: Rising prevalence of orphan and rare diseases

Increase in focus on manufacturing drugs for rare diseases by pharmaceutical entities focusing is expected to drive the clinical trials market growth in the near future. This is attributed to the technical advancements that enhance genetic identification of rare disorders. Additionally, incentives and initiatives implemented across the globe targeted towards development of orphan drugs as rare disorder therapeutics has also been witnessed. In 2020 as well, significant progress has been seen in this area. In 2020, FDA approved more than 30 novel drugs as well as biologics that have orphan drug designation. Whereas, in the Center for Drug Evaluation and Research (CDER) 80% of novel drug approvals were orphan designated products. Elevating approvals of orphan drugs has encouraged the clinical trial service providers to expand their portfolio, thereby driving the market growth.

Challenges: Requirement of unique analytical testing approaches for innovative drug molecules

The field of therapeutics has witnessed immense competition over the years, wherein both established and emerging pharmaceutical companies are rushing to develop novel therapeutics to gain exclusive patents. Bioanalytical testing plays a key role across all phases of pharmaceutical development, and is largely outsourced element in the clinical trial activities. Effective analytical testing solutions are imperative to meet regulatory mandates, this helps in attaining speedy approval of investigational New Drug (IND) products. Diverse CMC requirements pose challenges for analytical methods being developed for testing new drug molecules.

Opportunity:Rising demand for specialized testing services among end users

In recent years, partnering earlier in the drug development process as part of an effort to create efficiencies is a growing trend. Companies are increasingly outsourcing specialized testing services such as Liquid Chromatography-Mass Spectrometry (LC/MS), RNA sequencing, gene expression analysis, wet chemistry analysis of compendia raw materials, trace metal analysis with Inductively Coupled Mass Spectrometry (ICP-MS), and various others much earlier in the API process development cycle. These specialized services are mainly used for structural elucidation of key impurities, removing class I and II solvents, hazards analysis, removal of column chromatography, and efforts toward overall cost reduction and process efficiency.

Market Trends: Adoption of artificial intelligence-based tools for drug discovery

Advent of artificial intelligence (AI) has made the process of drug discovery very efficient while improving success rates of drug development substantially. AI algorithms aid in the analysis of data in vast amounts further facilitating the identification of potential drug candidates in lesser time. Additionally, deep learning systems are also being used to generate drug candidates that exhibit no adverse effects upon administration. Benefits associated with the integration of AI in drug discovery process have propelled clinical trial service provoders to adopt AI solutions.

By phase, Phase III segment accounted for the largest share of the clinical trials market in 2020.

Based on phase, the clinical trials market is segmented into Phase I, Phase II, Phase III, & Phase IV. Phase III has dominated the clinical trials market in 2020, attributed to the large-scale testing. This offers pharmaceutical entities and the regulatory authorities (FDA) a detailed understanding of the drug or medical efficacy and adverse effects. Phase III consists of Phase IIIa and IIIb wherein Phase IIIa studies aim at obtaining statistical evidence regarding drug safety and efficacy speeding up the approval process. Phase IIIb studies begin before the approval and are not intended for regulatory submissions.

By service type, the clinical trial data management services segment is expected to record the highest growth in the clinical trials market during the forecast period.

Based on service type, the clinical trial services market is segmented into protocol designing, site identification, patient recruitment, laboratory services, bioanalytical testing, analytical testing, clinical trial supply & logistic services, decentralized clinical services, clinical trial data management services, medical device testing services, and other services. Several CROs offer data management services that cater to the needs of medical device manufacturers, pharmaceutical manufacturers, and biopharmaceutical companies. These include supervision and development plans or policies that enhance value of data acquired in the clinical trial market space. Such advantages have increased the preference towards outsourcing clinical data management propelling segment growth.

By therapy area, oncology segment accounted for the largest share of the clinical trials market in 2020

Based on the therapy area, the clinical trials market is segmented into oncology, infectious diseases, cardiology, neurology, women’s health, genetic diseases, immunology, and other therapy areas. Cancer represents a significant opportunity for healthcare professionals across the globe. As reported by the American Cancer Society, more than half of the country’s total healthcare spending is dedicated to cancer. Robust funding has also encouraged companies to develop novel medicines for cancer which is set to drive the segment growth.

By application, the vaccine segment is expected to record the highest growth in the clinical trials market during the forecast period.

Based on application, the global clinical trial market is segmented into small applications, vaccines, cell & gene therapy, and others. The outbreak of SARS-CoV-2 infection has supplemented the considerable increase in the number of clinical trials registered in the past 2 years. Approximately 1000 new trials have been registered to against COVID-19 which has encouraged clinical research service providers with vaccine expertise to expand their service portfolio and help in troubleshooting the issues faced vaccine enrolment goals and start-up timelines. These service providers include IQVIA (US), Avantor, Inc. (US), CVS Health (US), and Viroclinics Biosciences (Netherlands).

North America accounted for the largest share of the clinical trials market in 2020.

In 2020, North America accounted for the largest share of the clinical trials market. This is attributed to the robust contribution of the US in North America clinical trials market. The US serves as a global hub for clinical trials, wherein majority of pharmaceutical development research is conducted, as it has a well-defined regulatory system along with advanced hospital infrastructure. As per the data by ClinicalTrials.gov, as of June 2021, there were 380,943 registered clinical studies worldwide. One-third of these, i.e., 123,890 registered clinical studies, were completed in the US.

Clinical Trials Market  by Region

To know about the assumptions considered for the study, download the pdf brochure

Key Market Players

IQVIA (US), LabCorp (US), Charles River Laboratories (US), WuXi AppTec (China), Syneos Health (US), PPD (US), and ICON Plc (US) are the prominent players operating in the clinical trials market.

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market Size Available for Years

2019–2026

Base Year Considered

2020

Forecast Period

2021–2026

Forecast Units

Value (USD)

Segments Covered

Phase, Service Type, Therapy Area, Application, and Region

Geographies Covered

North America, Europe, Asia Pacific, Latin America and Middle East & Africa

Companies Covered

The major market players include including IQVIA (US), LabCorp (US), Charles River Laboratories (US), WuXi AppTec (China), Syneos Health (US), Parexel International (US), PPD (US), ICON Plc (US), Medpace Holdings (US), SGS (Switzerland), PSI CRO AG (US), Axcent Advanced Analytics (US), BIO Agile Therapeutics (US), Firma Clinical Research (US), Acculab Life Sciences (US), Azelix (US), CTserv (US), Pepgra (UK), and Dove Quality Solutions (US), Novotech Health Holding (Australia), Geneticist Inc. (US), Linical Americas (US), Frontage Holding Corporation (US), and Celerion (US).

The study categorizes the clinical trials market into the following segments and subsegments:

BY PHASE

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

BY SERVICE TYPE

  • Protocol Designing
  • Site Identification
  • Patient Recruitment
  • Laboratory Services
  • Bioanalytical Testing Services
    • Cell-based Assays
    • Virology Testing
    • Method Development, Optimization, & Validation
    • Serology, Immunogenicity, & Neutralizing Antibodies
    • Biomarker Testing Services
    • PK/PD (Pharmacokinetics/Pharmacodynamics) Testing Services
    • Other Bioanalytical Testing Services
  • Analytical Testing Services
  • Clinical Trial Supply & Logistic Services
  • Decentralized Clinical Services
  • Clinical Trial Data Management Services
  • Medical Device Testing Services
  • Other Clinical Trial Services

BY THERAPY AREA

  • Oncology
  • Infectious Diseases
  • Cardiology
  • Neurology
  • Women's Health
  • Genetic Diseases
  • Immunology
  • Other Therapy Areas

BY APPLICATION

  • Vaccine
  • Cell & Gene Therapy
  • Small Molecules
  • Other Applications

BY REGION

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
  • The Middle East and Africa

Recent Developments

  • In September 2021, Syneos Health entered into a strategic collaboration with Ride Health to offer non-emergency medical transportation (NEMT) for clinical trial participants.
  • In April 2021, IQVIA acquired Q2 Solutions, a clinical laboratory services organization, from Quest Diagnostics.
  • In November 2020, WuXi Apptec expanded its Cell & Gene Therapy Platforms with capabilities to provide high-quality and cost-effective supplies of R&D and GMP Plasmids
  • In April 2020, IQVIA launched COVID-19 trial matching service to accelerate treatment and vaccine development against the COVID-19 pandemic in U.S. The company launched comprehensive online screener and trial matching tool for all COVID-19 trials in the US.
  • In May 2020, IQVIA announced the Japan and Asia Pacific expansion of IQVIA Biotech to deliver integrated clinical solutions and support biotech and emerging biopharma companies.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 40)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE
           FIGURE 1 CLINICAL TRIALS MARKET
           1.3.1 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 44)
    2.1 RESEARCH DATA
           FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 3 CLINICAL TRIALS MARKET: BREAKDOWN OF PRIMARIES
    2.2 MARKET SIZE ESTIMATION
           FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF CLINICAL TRIALS IN THE MARKET
           FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2020
           FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2020
    2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
           FIGURE 7 CLINICAL TRIALS MARKET: CAGR PROJECTIONS, 2021–2026
           FIGURE 8 CLINICAL TRIALS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, AND OPPORTUNITIES
           FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
           FIGURE 10 DATA TRIANGULATION METHODOLOGY
    2.5 INSIGHTS FROM PRIMARIES
           FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS
    2.6 RESEARCH ASSUMPTIONS
           2.6.1 COVID-19 SPECIFIC ASSUMPTIONS
    2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY (Page No. - 56)
    FIGURE 12 CLINICAL TRIALS MARKET, BY PHASE, 2021 VS. 2026 (USD BILLION)
    FIGURE 13 CLINICAL TRIALS MARKET, BY THERAPY AREA, 2021 VS. 2026 (USD BILLION)
    FIGURE 14 CLINICAL TRIALS MARKET, BY APPLICATION, 2021 VS. 2026 (USD BILLION)
    FIGURE 15 CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021 VS. 2026 (USD BILLION)
    FIGURE 16 GEOGRAPHICAL SNAPSHOT: CLINICAL TRIALS MARKET

4 PREMIUM INSIGHTS (Page No. - 60)
    4.1 CLINICAL TRIALS MARKET OVERVIEW
           FIGURE 17 RISING INVESTMENTS IN THE PHARMACEUTICAL INDUSTRY TO DRIVE THE MARKET GROWTH
    4.2 NORTH AMERICA: CLINICAL TRIALS MARKET SHARE, BY PHASE & COUNTRY (2020)
           FIGURE 18 PHASE III SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN CLINICAL TRIALS MARKET IN 2020
    4.3 CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICE TYPE, 2021 VS. 2026 (USD BILLION)
           FIGURE 19 CELL-BASED ASSAY SEGMENT CONTINUES TO DOMINATE THE MARKET DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 63)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 20 CLINICAL TRIALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           TABLE 1 CLINICAL TRIALS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing investment in pharmaceutical R&D
                               FIGURE 21 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2026
                               FIGURE 22 ACTIVE PHARMACEUTICAL PIPELINE, 2011–2021
                    5.2.1.2 Increasing number of clinical trials
                               FIGURE 23 NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (2000–2021)
                    5.2.1.3 High cost of in-house drug development
                               FIGURE 24 AVERAGE COST TO DEVELOP A PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2010–2020 (USD BILLION)
                    5.2.1.4 Rising prevalence of orphan and rare diseases
           5.2.2 OPPORTUNITIES
                    5.2.2.1 Growth in drugs and biologics market despite COVID-19 pandemic
                               FIGURE 25 TOTAL NUMBER OF NEW DRUGS (NEW CHEMICAL ENTITIES AND BIOLOGICS) APPROVED BY US FDA (2001–2020)
                               TABLE 2 LIST OF BIOLOGICS APPROVED BY US FDA, 2020
                    5.2.2.2 Rising demand for specialized testing services among end users
                    5.2.2.3 Need for novel clinical trial designs for complex cell and gene therapies
           5.2.3 CHALLENGES
                    5.2.3.1 Shortage of skilled professionals for clinical trials
                    5.2.3.2 Requirement of unique analytical testing approaches for innovative drug molecules
           5.2.4 MARKET TRENDS
                    5.2.4.1 Adoption of artificial intelligence-based tools for drug discovery
                    5.2.4.2 Increasing outsourcing activities in emerging Asian economies
                    5.2.4.3 Integrated end-to-end R&D service solutions
    5.3 RANGES/SCENARIOS
           FIGURE 26 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE CLINICAL TRIALS MARKET
    5.4 IMPACT OF COVID-19 ON CLINICAL TRIALS MARKET
    5.5 PORTER’S FIVE FORCES ANALYSIS
           TABLE 3 CLINICAL TRIALS MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.5.1 THREAT OF NEW ENTRANTS
           5.5.2 THREAT OF SUBSTITUTES
           5.5.3 BARGAINING POWER OF BUYERS
           5.5.4 BARGAINING POWER OF SUPPLIERS
           5.5.5 DEGREE OF COMPETITION
    5.6 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
           FIGURE 27 REVENUE SHIFT & NEW POCKETS FOR CLINICAL TRIAL SERVICE PROVIDERS
    5.7 ECOSYSTEM ANALYSIS
           FIGURE 28 ECOSYSTEM ANALYSIS: CLINICAL TRIALS MARKET
           TABLE 4 SUPPLY CHAIN ECOSYSTEM
    5.8 REGULATORY ANALYSIS

6 CLINICAL TRIALS MARKET, BY PHASE (Page No. - 82)
    6.1 INTRODUCTION
           TABLE 5 CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)
           FIGURE 29 DRUGS IN THE PIPELINE, BY DEVELOPMENT PHASE, 2019 VS. 2020
    6.2 CLINICAL TRIALS PLANNING AND DESIGNING SOLUTION
           FIGURE 30 CLINICAL TRIAL PLANNING & DESIGNING
    6.3 PHASE I
           6.3.1 ROBUST PIPELINE OF PHARMACEUTICAL COMPANIES DRIVES THE GROWTH OF THIS SEGMENT
                    TABLE 6 EXAMPLES OF PHASE I STUDY OF DRUGS
                    TABLE 7 PHASE I CLINICAL TRIALS MARKET, BY REGION, 2019–2026 (USD BILLION)
                    TABLE 8 NORTH AMERICA: PHASE I CLINICAL TRIALS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 9 EUROPE: PHASE I CLINICAL TRIALS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 10 ASIA PACIFIC: PHASE I CLINICAL TRIALS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
    6.4 PHASE II
           6.4.1 LONG DURATION OF PHASE II STUDIES PROVIDES GROWTH OPPORTUNITIES FOR CROS
                    TABLE 11 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE II STUDIES
                    TABLE 12 PHASE II CLINICAL TRIALS MARKET, BY REGION, 2019–2026 (USD BILLION)
                    TABLE 13 NORTH AMERICA: PHASE II CLINICAL TRIALS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 14 EUROPE: PHASE II CLINICAL TRIALS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 15 ASIA PACIFIC: PHASE II CLINICAL TRIALS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
    6.5 PHASE III
           6.5.1 RISING COSTS OF PHASE III TRIALS INCREASES THE DEMAND FOR COST-EFFECTIVE CLINICAL RESEARCH SERVICES
                    TABLE 16 EXAMPLES OF DRUGS THAT HAVE COMPLETED THE PHASE III STUDY
                    TABLE 17 PHASE III CLINICAL TRIALS MARKET, BY REGION, 2019–2026 (USD BILLION)
                    TABLE 18 NORTH AMERICA: PHASE III CLINICAL TRIALS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 19 EUROPE: PHASE III CLINICAL TRIALS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 20 ASIA PACIFIC: PHASE III CLINICAL TRIALS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
    6.6 PHASE IV
           6.6.1 RISING NUMBER OF CLINICAL RESEARCH ENTITIES PROVIDING POST-MARKETING SURVEILLANCE TO DRIVE THE SEGMENT GROWTH
                    TABLE 21 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE IV CLINICAL STUDIES
                    TABLE 22 PHASE IV CLINICAL TRIALS MARKET, BY REGION, 2019–2026 (USD BILLION)
                    TABLE 23 NORTH AMERICA: PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 24 EUROPE: PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 25 ASIA PACIFIC: PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)

7 CLINICAL TRIALS MARKET, BY SERVICE TYPE (Page No. - 97)
    7.1 INTRODUCTION
           TABLE 26 CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2026 (USD BILLION)
    7.2 PROTOCOL DESIGNING
           7.2.1 PROTOCOL DESIGNING SERVICES SERVE AS AN EFFECTIVE STRATEGY TO ENSURE RAPID & EFFECTIVE PLANNING FOR CLINICAL TRIAL STUDIES
                    TABLE 27 PROTOCOL DESIGNING MARKET, BY REGION, 2019–2026 (USD BILLION)
                    TABLE 28 NORTH AMERICA: PROTOCOL DESIGNING MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 29 EUROPE: PROTOCOL DESIGNING MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 30 ASIA PACIFIC: PROTOCOL DESIGNING MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
    7.3 SITE IDENTIFICATION
           7.3.1 NEW DIGITAL TECHNOLOGIES THAT ENABLE DATA VARIABILITY ENHANCES SITE IDENTIFICATION SERVICE EFFICACY
                    TABLE 31 SITE IDENTIFICATION MARKET, BY REGION, 2019–2026 (USD BILLION)
                    TABLE 32 NORTH AMERICA: SITE IDENTIFICATION MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 33 EUROPE: SITE IDENTIFICATION MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 34 ASIA PACIFIC: SITE IDENTIFICATION MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
    7.4 PATIENT RECRUITMENT
           7.4.1 GROWING REQUIREMENT TO WORK WITH A PATIENT-CENTRIC CLINICAL TRIAL COMPANY SUPPORTS THE GROWTH OF THIS SEGMENT
                    TABLE 35 SOME OF THE PATIENT RECRUITMENT SERVICE PROVIDERS
                    TABLE 36 PATIENT RECRUITEMENT MARKET, BY REGION, 2019–2026 (USD BILLION)
                    TABLE 37 NORTH AMERICA: PATIENT RECRUITEMENT MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 38 EUROPE: PATIENT RECRUITEMENT MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 39 ASIA PACIFIC: PATIENT RECRUITEMENT MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
    7.5 LABORATORY SERVICES
           7.5.1 INCREASING IMPORTANCE OF LABORATORY SERVICES TO ENSURE REGULATORY COMPLIANCE PROPELS THE GROWTH OF THIS SEGMENT
                    TABLE 40 EXAMPLES OF LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS
                    TABLE 41 LABORATORY SERVICES MARKET, BY REGION, 2019–2026 (USD BILLION)
                    TABLE 42 NORTH AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 43 EUROPE: LABORATORY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 44 ASIA PACIFIC: LABORATORY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
           7.5.2 ANALYTICAL TESTING SERVICES
                    7.5.2.1 Increasing demand for analytical testing for drug development to drive the growth of this segment
                               TABLE 45 ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2019–2026 (USD BILLION)
                               TABLE 46 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                               TABLE 47 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                               TABLE 48 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
    7.6 BIOANALYTICAL TESTING SERVICES
           7.6.1 HIGH DEMAND FOR BIOANALYTICAL TESTING DUE TO THE GROWING USE OF MACROMOLECULES AND BIOSIMILARS TO DRIVE THE GROWTH OF THIS SEGMENT
                    TABLE 49 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD BILLION)
                    TABLE 50 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2019–2026 (USD BILLION)
                    TABLE 51 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 52 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 53 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
           7.6.2 CELL-BASED ASSAYS
                    7.6.2.1 Increasing number of service providers offering customized cell-based assay testing services to drive the growth of this segment
                               TABLE 54 CELL-BASED ASSAYS MARKET, BY REGION, 2019–2026 (USD BILLION)
                               TABLE 55 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                               TABLE 56 EUROPE: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                               TABLE 57 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
           7.6.3 VIROLOGY TESTING
                    7.6.3.1 Higher uptake of in vitro virology assays in the development of antiviral pharmaceuticals to drive the growth of this segment
                               TABLE 58 VIROLOGY TESTING MARKET, BY REGION, 2019–2026 (USD BILLION)
                               TABLE 59 NORTH AMERICA: VIROLOGY TESTING MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                               TABLE 60 EUROPE: VIROLOGY TESTING MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                               TABLE 61 ASIA PACIFIC: VIROLOGY TESTING MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
           7.6.4 PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES
                    7.6.4.1 Rising importance of studies to determine pharmacokinetic behavior of drug candidates to drive the growth of this segment
                               TABLE 62 PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY REGION, 2019–2026 (USD BILLION)
                               TABLE 63 NORTH AMERICA: PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                               TABLE 64 EUROPE: PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                               TABLE 65 ASIA PACIFIC: PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
           7.6.5 METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION
                    7.6.5.1 Increasing preference of biopharmaceutical companies to outsource method validation services for clinical trials to drive this segment
                               TABLE 66 METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET, BY REGION, 2019–2026 (USD BILLION)
                               TABLE 67 NORTH AMERICA: METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                               TABLE 68 EUROPE: METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                               TABLE 69 ASIA PACIFIC: METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
           7.6.6 SEROLOGY, IMMUNOGENICITY, & NEUTRALIZING ANTIBODIES
                    7.6.6.1 High demand for immunogenicity and neutralizing antibody assays in biosimilar development to propel market growth
                               TABLE 70 SEROLOGY, IMMUNOGENICITY, & NEURTALIZING ANTIBODIES MARKET, BY REGION, 2019–2026 (USD BILLION)
                               TABLE 71 NORTH AMERICA: SEROLOGY, IMMUNOGENICITY, & NEURTALIZING ANTIBODIES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                               TABLE 72 EUROPE: SEROLOGY, IMMUNOGENICITY, & NEURTALIZING ANTIBODIES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                               TABLE 73 ASIA PACIFIC: SEROLOGY, IMMUNOGENICITY, & NEURTALIZING ANTIBODIES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
           7.6.7 BIOMARKER TESTING SERVICES
                    7.6.7.1 Growing emphasis on biomarker testing to develop personalized medicines and companion diagnostics to augment segment growth
                               TABLE 74 BIOMARKER TESTING SERVICES MARKET, BY REGION, 2019–2026 (USD BILLION)
                               TABLE 75 NORTH AMERICA: BIOMARKER TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                               TABLE 76 EUROPE: BIOMARKER TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                               TABLE 77 ASIA PACIFIC: BIOMARKER TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
           7.6.8 OTHER BIOANALYTICAL TESTING SERVICES
                    TABLE 78 OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2019–2026 (USD BILLION)
                    TABLE 79 NORTH AMERICA: OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 80 EUROPE: OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 81 ASIA PACIFIC: OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
    7.7 CLINICAL TRIAL DATA MANAGEMENT SERVICES
           7.7.1 DATA MANAGEMENT SERVICES SEGMENT IS EXPECTED TO RECORD THE HIGHEST CAGR DURING THE FORECAST PERIOD
                    TABLE 82 EXAMPLES OF DATA MANAGEMENT SERVICES OFFERED BY PROMINENT PLAYERS
                    TABLE 83 CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY REGION, 2019–2026 (USD BILLION)
                    TABLE 84 NORTH AMERICA: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 85 EUROPE: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 86 ASIA PACIFIC: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
    7.8 CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES
           7.8.1 ADVANCED DATA ANALYTICS INCORPORATED IN CLINICAL TRIAL SUPPLY MANAGEMENT IS EXPECTED TO DRIVE THE GROWTH OF THIS SEGMENT
                    TABLE 87 CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY REGION, 2019–2026 (USD BILLION)
                    TABLE 88 NORTH AMERICA: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 89 EUROPE: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 90 ASIA PACIFIC: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
    7.9 DECENTRALIZED CLINICAL TRIAL SERVICES
           7.9.1 THE SARS-COV-2 OUTBREAK HAS SIGNIFICANTLY CATALYZED THE DEMAND FOR DECENTRALIZED CLINICAL TRIALS
                    TABLE 91 DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY REGION, 2019–2026 (USD BILLION)
                    TABLE 92 NORTH AMERICA: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 93 EUROPE: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 94 ASIA PACIFIC: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
    7.10 MEDICAL DEVICE TESTING SERVICES
           7.10.1 INCREASING R&D FOR THE DEVELOPMENT OF ADVANCED MEDICAL DEVICES TO DRIVE THE GROWTH OF THIS MARKET
                    TABLE 95 MEDICAL DEVICE TESTING SERVICES MARKET, BY REGION, 2019–2026 (USD BILLION)
                    TABLE 96 NORTH AMERICA: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 97 EUROPE: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 98 ASIA PACIFIC: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
    7.11 OTHER CLINICAL TRIAL SERVICES
           7.11.1 OTHER CLINICAL TRIAL SERVICES SEGMENT INCLUDES CONSULTING SERVICES, MEDICAL WRITING SERVICES, AND PHARMACOGENOMICS TESTING SERVICES
                    TABLE 99 OTHER CLINICAL TRIAL SERVICES MARKET, BY REGION, 2019–2026 (USD BILLION)
                    TABLE 100 NORTH AMERICA: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 101 EUROPE: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 102 ASIA PACIFIC: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)

8 CLINICAL TRIALS MARKET, BY THERAPY AREA (Page No. - 135)
    8.1 INTRODUCTION
           TABLE 103 CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019–2026 (USD BILLION)
    8.2 ONCOLOGY
           8.2.1 RISING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH
                    FIGURE 31 GLOBAL CANCER INCIDENCE, BY TYPE (2020)
                    FIGURE 32 ONCOLOGY CLINICAL TRIALS GLOBALLY, 2010-2018 (THOUSAND)
                    TABLE 104 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2020)
                    TABLE 105 CLINICAL TRIALS MARKET FOR ONCOLOGY, BY REGION, 2019–2026 (USD BILLION)
                    TABLE 106 NORTH AMERICA: CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 107 EUROPE: CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 108 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026 (USD BILLION)
    8.3 INFECTIOUS DISEASES
           8.3.1 INFECTIOUS DISEASES SEGMENT TO REGISTER THE HIGHEST GROWTH RATE IN THE FORECAST PERIOD
                    TABLE 109 CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2019–2026 (USD BILLION)
                    TABLE 110 NORTH AMERICA: CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 111 EUROPE: CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 112 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD BILLION)
    8.4 NEUROLOGY
           8.4.1 INCREASING INVESTMENTS IN R&D AND GRANTS FOR NEUROLOGICAL DISORDERS TO DRIVE MARKET GROWTH
                    TABLE 113 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2020)
                    TABLE 114 CLINICAL TRIALS MARKET FOR NEUROLOGY, BY REGION, 2019–2026 (USD BILLION)
                    TABLE 115 NORTH AMERICA: CLINICAL TRIALS MARKET FOR NEUROLOGY, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 116 EUROPE: CLINICAL TRIALS MARKET FOR NEUROLOGY, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 117 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR NEUROLOGY, BY COUNTRY, 2019–2026 (USD BILLION)
    8.5 IMMUNOLOGY
           8.5.1 GROWING PIPELINE OF IMMUNOLOGICAL DRUGS HAS RESULTED IN INCREASING OUTSOURCING ACTIVITIES
                    TABLE 118 CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY REGION, 2019–2026 (USD BILLION)
                    TABLE 119 NORTH AMERICA: CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 120 EUROPE: CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 121 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2019–2026 (USD BILLION)
    8.6 CARDIOLOGY
           8.6.1 HIGH MORTALITY RATES ARE DRIVING PHARMACEUTICAL COMPANIES TO DEVELOP NEW TREATMENT OPTIONS
                    TABLE 122 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2020)
                    TABLE 123 CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY REGION, 2019–2026 (USD BILLION)
                    TABLE 124 NORTH AMERICA: CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 125 EUROPE: CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 126 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY COUNTRY, 2019–2026 (USD BILLION)
    8.7 GENETIC DISEASES
           8.7.1 PROMISING DRUGS IN PIPELINE FOR RARE DISEASES TO SUPPORT MARKET GROWTH
                    TABLE 127 CLINICAL TRIALS MARKET FOR GENETIC DISEASES, BY REGION, 2019–2026 (USD BILLION)
                    TABLE 128 NORTH AMERICA: CLINICAL TRIALS MARKET FOR GENETIC DISEASES, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 129 EUROPE: CLINICAL TRIALS MARKET FOR GENETIC DISEASES, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 130 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR GENETIC DISEASES, BY COUNTRY, 2019–2026 (USD BILLION)
    8.8 WOMEN’S HEALTH
           8.8.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO DRIVE MARKET GROWTH
                    TABLE 131 CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH, BY REGION, 2019–2026 (USD BILLION)
                    TABLE 132 NORTH AMERICA: CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 133 EUROPE: CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 134 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH, BY COUNTRY, 2019–2026 (USD BILLION)
    8.9 OTHER THERAPY AREAS
           FIGURE 33 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000-2045 (MILLION)
           TABLE 135 LIST OF PIPELINE DRUGS FOR SKIN DISEASES (2020)
           TABLE 136 CLINICAL TRIALS MARKET FOR OTHER THERAPY AREAS, BY REGION, 2019–2026 (USD BILLION)
           TABLE 137 NORTH AMERICA: CLINICAL TRIALS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2019–2026 (USD BILLION)
           TABLE 138 EUROPE: CLINICAL TRIALS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2019–2026 (USD BILLION)
           TABLE 139 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2019–2026 (USD BILLION)

9 CLINICAL TRIALS MARKET, BY APPLICATION (Page No. - 156)
    9.1 INTRODUCTION
           TABLE 140 CLINICAL TRIAL MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
    9.2 SMALL MOLECULE
           9.2.1 INCREASING INVESTMENTS BY VIRTUAL AND SMALLER COMPANIES TO DRIVE SMALL MOLECULE DEVELOPMENT PROJECTS SUPPORTS THE GROWTH OF THIS SEGMENT
                    FIGURE 34 SMALL MOLECULE PIPELINE: NEW CHEMICAL ENTITY, 2014-2019
                    TABLE 141 CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY REGION, 2019–2026 (USD BILLION)
                    TABLE 142 NORTH AMERICA: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 143 EUROPE: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 144 ASIA PACIFIC: CLINICAL TRIAL MARKET FOR SMALL MOLECULES, BY COUNTRY, 2019–2026 (USD BILLION)
    9.3 VACCINES
           9.3.1 OUTBREAK OF THE COVID-19 PANDEMIC IS EXPECTED TO EMERGE AS A MARKET DISRUPTOR, IMPOSING LONG-TERM POSITIVE EFFECTS ON THE INDUSTRY OPERATIONS
                    FIGURE 35 COVID-19 VACCINE CANDIDATES IN CLINICAL DEVELOPMENT, BY PHASE (AS OF JANUARY 2022)
                    TABLE 145 CLINICAL TRIALS MARKET FOR VACCINES, BY REGION, 2019–2026 (USD BILLION)
                    TABLE 146 NORTH AMERICA: CLINICAL TRIALS MARKET FOR VACCINES, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 147 EUROPE: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR VACCINES, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 148 ASIA PACIFIC: CLINICAL TRIALS MARKET FORCLINICAL TRIALS MARKET FOR VACCINES, BY COUNTRY, 2019–2026 (USD BILLION)
    9.4 CELL & GENE THERAPY
           9.4.1 THE RISING TREND OF OUTSOURCING SERVICES AND THE ONGOING EFFORTS OF SERVICE PROVIDERS TO EXPAND THEIR RESPECTIVE OFFERINGS IS DRIVING THE CLINICAL DEVELOPMENT PIPELINE FOR CELL & GENE THERAPY
                    FIGURE 36 ACTIVE CLINICAL TRIALS FOR CELL & GENE THERAPY, BY INDICATION (AS OF 2020)
                    FIGURE 37 ACTIVE CLINICAL TRIALS FOR CELL & GENE THERAPY, BY PHASE (2020)
                    TABLE 149 CLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY REGION, 2019–2026 (USD BILLION)
                    TABLE 150 NORTH AMERICA: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 151 EUROPE: CLINICAL TRIALS MARKET FORCLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 152 ASIA PACIFIC: CLINICAL TRIALS MARKET FORCLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2019–2026 (USD BILLION)
    9.5 OTHER APPLICATIONS
           9.5.1 INCREASE IN R&D FOR THE DEVELOPMENT OF HORMONES AND BLOOD COMPONENTS SUPPORTS MARKET GROWTH
                    TABLE 153 CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY REGION, 2019–2026 (USD BILLION)
                    TABLE 154 NORTH AMERICA: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 155 EUROPE: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD BILLION)
                    TABLE 156 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD BILLION)

10 CLINICAL TRIALS MARKET, BY REGION (Page No. - 168)
     10.1 INTRODUCTION
               TABLE 157 CLINICAL TRIALS MARKET, BY REGION, 2019–2026 (USD BILLION)
     10.2 NORTH AMERICA
               FIGURE 38 NORTH AMERICA SNAPSHOT
               TABLE 158 NORTH AMERICA: CLINICAL TRIALS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
               TABLE 159 NORTH AMERICA: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)
               TABLE 160 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY SERVICE TYPE, 2019–2026 (USD BILLION)
               TABLE 161 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY BIOANALYTICAL SERVICES, 2019–2026 (USD BILLION)
               TABLE 162 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY THERAPY AREA, 2019–2026 (USD BILLION)
               TABLE 163 NORTH AMERICA: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
             10.2.1 US
                       10.2.1.1 Robust clinical research activities to become a key factor supporting the US market growth
                                   FIGURE 39 US CONTINUES TO DOMINATE THE DISTRIBUTION OF R&D COMPANIES BY REGION (2020 VS. 2019)
                                   TABLE 164 US: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)
                                   TABLE 165 US: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2026 (USD BILLION)
                                   TABLE 166 US: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019–2026 (USD BILLION)
                                   TABLE 167 US: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019–2026 (USD BILLION)
                                   TABLE 168 US: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
             10.2.2 CANADA
                       10.2.2.1 Increasing number of clinical trials in Canada to support market growth
                                   TABLE 169 CANADA: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)
                                   TABLE 170 CANADA: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2026 (USD BILLION)
                                   TABLE 171 CANADA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019–2026 (USD BILLION)
                                   TABLE 172 CANADA: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019–2026 (USD BILLION)
                                   TABLE 173 CANADA: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
     10.3 EUROPE
               FIGURE 40 CLINICAL TRIALS CONDUCTED IN EUROPE SINCE 2008 (2018)
               TABLE 174 EUROPE: CLINICAL TRIALS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
               TABLE 175 EUROPE: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)
               TABLE 176 EUROPE: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2026 (USD BILLION)
               TABLE 177 EUROPE: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019–2026 (USD BILLION)
               TABLE 178 EUROPE: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019–2026 (USD BILLION)
               TABLE 179 EUROPE: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
             10.3.1 GERMANY
                       10.3.1.1 Government support and flexible labor laws have made Germany a favorable location for clinical trials
                                   TABLE 180 GERMANY: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)
                                   TABLE 181 GERMANY: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2026 (USD BILLION)
                                   TABLE 182 GERMANY: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019–2026 (USD BILLION)
                                   TABLE 183 GERMANY: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019–2026 (USD BILLION)
                                   TABLE 184 GERMANY: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
             10.3.2 UK
                       10.3.2.1 Investments by pharmaceutical sponsors in the UK for drug discovery services to support market growth
                                   FIGURE 41 UK: PHARMACEUTICAL R&D EXPENDITURE, 2013–2017 (USD MILLION)
                                   TABLE 185 UK: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)
                                   TABLE 186 UK: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2026 (USD BILLION)
                                   TABLE 187 UK: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019–2026 (USD BILLION)
                                   TABLE 188 UK: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019–2026 (USD BILLION)
                                   TABLE 189 UK: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
             10.3.3 FRANCE
                       10.3.3.1 High number of oncology clinical trials in France is expected to drive market growth in France
                                   TABLE 190 FRANCE: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)
                                   TABLE 191 FRANCE: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2026 (USD BILLION)
                                   TABLE 192 FRANCE: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019–2026 (USD BILLION)
                                   TABLE 193 FRANCE: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019–2026 (USD BILLION)
                                   TABLE 194 FRANCE: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
             10.3.4 ITALY
                       10.3.4.1 Low drug approval times along with the growing number of clinical trials in Italy to drive market growth
                                   TABLE 195 NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY (JANUARY 2021)
                                   TABLE 196 ITALY: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)
                                   TABLE 197 ITALY: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2026 (USD BILLION)
                                   TABLE 198 ITALY: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019–2026 (USD BILLION)
                                   TABLE 199 ITALY: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019–2026 (USD BILLION)
                                   TABLE 200 ITALY: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
             10.3.5 SPAIN
                       10.3.5.1 Rising R&D expenditure to boost market growth for clinical trials in Spain
                                   FIGURE 42 SPAIN: PHARMACEUTICAL R&D EXPENDITURE (USD MILLION), 2011–2017
                                   TABLE 201 SPAIN: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)
                                   TABLE 202 SPAIN: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2026 (USD BILLION)
                                   TABLE 203 SPAIN: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019–2026 (USD BILLION)
                                   TABLE 204 SPAIN: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019–2026 (USD BILLION)
                                   TABLE 205 SPAIN: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
             10.3.6 REST OF EUROPE (ROE)
                                   TABLE 206 ROE: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)
                                   TABLE 207 ROE: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2026 (USD BILLION)
                                   TABLE 208 ROE: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019–2026 (USD BILLION)
                                   TABLE 209 ROE: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019–2026 (USD BILLION)
                                   TABLE 210 ROE: CLINICAL TRIALS MARKET, BY MOLECULE, 2019–2026 (USD BILLION)
     10.4 ASIA PACIFIC (APAC)
               FIGURE 43 ASIA PACIFIC SNAPSHOT
               TABLE 211 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
               TABLE 212 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)
               TABLE 213 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2026 (USD BILLION)
               TABLE 214 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019–2026 (USD BILLION)
               TABLE 215 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019–2026 (USD BILLION)
               TABLE 216 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
             10.4.1 CHINA
                       10.4.1.1 China dominates the clinical trials services market owing to a robust pharmaceutical industry and presence of prominent clinical trial service providers
                                   TABLE 217 CHINA: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)
                                   TABLE 218 CHINA: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2026 (USD BILLION)
                                   TABLE 219 CHINA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019–2026 (USD BILLION)
                                   TABLE 220 CHINA: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019–2026 (USD BILLION)
                                   TABLE 221 CHINA: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
             10.4.2 JAPAN
                       10.4.2.1 Strong focus on R&D activities in Japan is expected to drive market growth
                                   TABLE 222 TOTAL NUMBER OF CLINICAL TRIALS IN JAPAN, BY THERAPEUTIC AREA, 2017 VS. 2019
                                   TABLE 223 JAPAN: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)
                                   TABLE 224 JAPAN: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2026 (USD BILLION)
                                   TABLE 225 JAPAN: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019–2026 (USD BILLION)
                                   TABLE 226 JAPAN: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019–2026 (USD BILLION)
                                   TABLE 227 JAPAN: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
             10.4.3 INDIA
                       10.4.3.1 Growing pharmaceutical industry in India to drive the market growth for clinical trails
                                   TABLE 228 TOTAL NUMBER OF CLINICAL TRIALS IN INDIA, BY THERAPEUTIC AREA, 2017 VS. 2019
                                   TABLE 229 INDIA: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)
                                   TABLE 230 INDIA: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2026 (USD BILLION)
                                   TABLE 231 INDIA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019–2026 (USD BILLION)
                                   TABLE 232 INDIA: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019–2026 (USD BILLION)
                                   TABLE 233 INDIA: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
             10.4.4 REST OF ASIA PACIFIC
                       TABLE 234 TOTAL NUMBER OF CLINICAL TRIALS IN SINGAPORE AND MALAYSIA, BY THERAPEUTIC AREA, 2017 VS. 2019
                       TABLE 235 ROAPAC: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)
                       TABLE 236 ROAPAC: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2026 (USD BILLION)
                       TABLE 237 ROAPAC: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019–2026 (USD BILLION)
                       TABLE 238 ROAPAC: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019–2026 (USD BILLION)
                       TABLE 239 ROAPAC: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
     10.5 LATIN AMERICA
             10.5.1 GROWING R&D EXPENDITURE IN THE PHARMACEUTICAL & BIOPHARMACEUTICAL SECTOR TO DRIVE THE MARKET GROWTH IN LATIN AMERICA
                       TABLE 240 LATIN AMERICA: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)
                       TABLE 241 LATIN AMERICA: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2026 (USD BILLION)
                       TABLE 242 LATIN AMERICA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019–2026 (USD BILLION)
                       TABLE 243 LATIN AMERICA: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019–2026 (USD BILLION)
                       TABLE 244 LATIN AMERICA: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
     10.6 MIDDLE EAST & AFRICA
             10.6.1 GROWING PHARMACEUTICAL INDUSTRY TO DRIVE THE MARKET GROWTH IN MIDDLE EAST & AFRICA
                       TABLE 245 MEA: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)
                       TABLE 246 MEA: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2026 (USD BILLION)
                       TABLE 247 MEA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019–2026 (USD BILLION)
                       TABLE 248 MEA: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019–2026 (USD BILLION)
                       TABLE 249 MEA: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 224)
     11.1 INTRODUCTION
     11.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
               FIGURE 44 CLINICAL TRIALS MARKET: STRATEGIES ADOPTED
     11.3 MARKET SHARE ANALYSIS
               FIGURE 45 CLINICAL TRIALS MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2020)
     11.4 COMPANY EVALUATION QUADRANT
             11.4.1 STARS
             11.4.2 EMERGING LEADERS
             11.4.3 PERVASIVE PLAYERS
             11.4.4 PARTICIPANTS
                       FIGURE 46 CLINICAL TRIALS MARKET: COMPANY EVALUATION MATRIX, 2020
     11.5 COMPETITIVE BENCHMARKING
             11.5.1 COMPANY SERVICE FOOTPRINT (20 COMPANIES)
                       FIGURE 47 SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE CLINICAL TRIALS MARKET
             11.5.2 COMPANY REGIONAL FOOTPRINT (20 COMPANIES)
                       FIGURE 48 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE CLINICAL TRIALS MARKET
     11.6 COMPETITIVE SCENARIO AND TRENDS
             11.6.1 SERVICES LAUNCHES
                       TABLE 250 CLINICAL TRIALS MARKET: SERVICE LAUNCHES JANUARY 2017-NOVEMBER 2020)
             11.6.2 DEALS
                       TABLE 251 CLINICAL TRIALS MARKET: DEALS (JANUARY 2017-SEPTEMBER 2021)
             11.6.3 OTHER DEVELOPMENTS
                       TABLE 252 CLINICAL TRIALS MARKET: EXPANSIONS (JANUARY 2017-NOVEMBER 2020)

12 COMPANY PROFILES (Page No. - 235)
     12.1 KEY COMPANIES
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
             12.1.1 IQVIA
                       TABLE 253 IQVIA: BUSINESS OVERVIEW
                       FIGURE 49 IQVIA: COMPANY SNAPSHOT
                       TABLE 254 IQVIA: SERVICE OFFERINGS
                       TABLE 255 IQVIA: SERVICE LAUNCHES
                       TABLE 256 IQVIA: DEALS
                       TABLE 257 IQVIA: OTHER DEVELOPMENTS
             12.1.2 LABCORP DRUG DEVELOPMENT (COVANCE)
                       TABLE 258 LABCORP: BUSINESS OVERVIEW
                       FIGURE 50 LABCORP: COMPANY SNAPSHOT
                       TABLE 259 LABCORP: SERVICE OFFERINGS
                       TABLE 260 LABCORP: SERVICE LAUNCHES
                       TABLE 261 LABCORP: DEALS
                       TABLE 262 LABCORP: EXPANSIONS
             12.1.3 SYNEOS HEALTH INC.
                       TABLE 263 SYNEOS HEALTH INC.: BUSINESS OVERVIEW
                       FIGURE 51 SYNEOS HEALTH INC.: COMPANY SNAPSHOT
                       TABLE 264 SYNEOS HEALTH INC.: SERVICE OFFERINGS
                       TABLE 265 SYNEOS HEALTH INC: SERVICE LAUNCHES
                       TABLE 266 SYNEOS HEALTH INC.: DEALS
             12.1.4 WUXI APPTEC
                       TABLE 267 WUXI APPTEC: BUSINESS OVERVIEW
                       FIGURE 52 WUXI APPTEC: COMPANY SNAPSHOT
                       TABLE 268 WUXI APPTEC: SERVICE OFFERINGS
                       TABLE 269 WUXI APPTEC: SERVICE LAUNCHES
                       TABLE 270 WUXI APPTEC: DEALS
                       TABLE 271 WUXI APPTEC: EXPANSIONS
             12.1.5 CHARLES RIVER LABORATORIES
                       TABLE 272 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW
                       FIGURE 53 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
                       TABLE 273 CHARLES RIVER LABORATORIES: SERVICE OFFERINGS
                       TABLE 274 CHARLES RIVER LABORATORIES: DEALS
                       TABLE 275 CHARLES RIVER LABORATORIES: EXPANSIONS
             12.1.6 PAREXEL INTERNATIONAL
                       TABLE 276 PAREXEL INTERNATIONAL: BUSINESS OVERVIEW
                       TABLE 277 PAREXEL INTERNATIONAL: SERVICE OFFERINGS
                       TABLE 278 PAREXEL INTERNATIONAL: SERVICE LAUNCHES
                       TABLE 279 PAREXEL INTERNATIONAL: DEALS
                       TABLE 280 PAREXEL INTERNATIONAL: EXPANSIONS
             12.1.7 PRA HEALTH SCIENCES
                       TABLE 281 PRA HEALTH SCIENCES: BUSINESS OVERVIEW
                       FIGURE 54 PRA HEALTH SCIENCES: COMPANY SNAPSHOT
                       TABLE 282 PRA HEALTH SCIENCES: SERVICE OFFERINGS
                       TABLE 283 PRA HEALTH SCIENCES: SERVICE LAUNCHES
                       TABLE 284 PRA HEALTH SCIENCES: DEALS
                       TABLE 285 PRA HEALTH SCIENCES: EXPANSIONS
             12.1.8 PPD INC
                       TABLE 286 PPD INC: BUSINESS OVERVIEW
                       FIGURE 55 PPD INC: COMPANY SNAPSHOT
                       TABLE 287 PPD INC: SERVICE OFFERINGS
                       TABLE 288 PPD: SERVICE LAUNCHES
                       TABLE 289 PPD: DEALS
                       TABLE 290 PPD: EXPANSIONS
             12.1.9 ICON PLC
                       TABLE 291 ICON PLC: BUSINESS OVERVIEW
                       FIGURE 56 ICON PLC: COMPANY SNAPSHOT
                       TABLE 292 ICON PLC: SERVICE OFFERINGS
                       TABLE 293 ICON PLC : SERVICE LAUNCHES
                       TABLE 294 ICON PLC: DEALS
             12.1.10 MEDPACE HOLDINGS INC
                       TABLE 295 MEDPACE HOLDINGS INC: BUSINESS OVERVIEW
                       FIGURE 57 MEDPACE HOLDINGS INC: COMPANY SNAPSHOT
                       TABLE 296 MEDPACE HOLDINGS INC: SERVICE OFFERINGS
                       TABLE 297 MEDPACE HOLDINGS INC: DEALS
                       TABLE 298 MEDPACE HOLDINGS INC: EXPANSION
             12.1.11 ACM GLOBAL LABORATORIES
                       TABLE 299 ACM GLOBAL LABORATORIES: BUSINESS OVERVIEW
                       TABLE 300 ACM GLOBAL LABORATORIES: SERVICE OFFERINGS
             12.1.12 ADVANCED CLINICAL
                       TABLE 301 ADVANCED CLINICAL: BUSINESS OVERVIEW
                       TABLE 302 ADVANCED CLINICAL: SERVICE OFFERINGS
             12.1.13 SGS
                       TABLE 303 SGS: BUSINESS OVERVIEW
                       FIGURE 58 SGS: COMPANY SNAPSHOT
                       TABLE 304 SGS: SERVICE OFFERINGS
                       TABLE 305 SGS: DEALS
             12.1.14 FRONTAGE HOLDINGS CORPORATION
                       TABLE 306 FRONTAGE HOLDINGS CORPORATION: BUSINESS OVERVIEW
                       FIGURE 59 FRONTAGE HOLDINGS CORPORATION: COMPANY SNAPSHOT
                       TABLE 307 FRONTAGE HOLDINGS CORPORATION: SERVICE OFFERINGS
                       TABLE 308 FRONTAGE HOLDINGS CORPORATION: DEALS
                       TABLE 309 FRONTAGE HOLDINGS CORPORATION: EXPANSION
             12.1.15 PSI CRO AG
                       TABLE 310 PSI CRO AG: BUSINESS OVERVIEW
                       TABLE 311 PSI CRO AG: SERVICE OFFERINGS
                       TABLE 312 PSI CRO AG: EXPANSIONS
             12.1.16 BIO AGILE THERAPEUTICS
                       TABLE 313 BIO AGILE THERAPEUTICS: BUSINESS OVERVIEW
                       TABLE 314 BIO AGILE THERAPEUTICS: SERVICE OFFERINGS
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
     12.2 OTHER PLAYERS
             12.2.1 AZELIX
                       TABLE 315 AZELIX: COMPANY OVERVIEW
             12.2.2 CTSERV
                       TABLE 316 CTSERV: COMPANY OVERVIEW
             12.2.3 PEPGRA
                       TABLE 317 PEPGRA: COMPANY OVERVIEW
             12.2.4 AXCENT ADVANCED ANALYTICS (A3)
                       TABLE 318 AXCENT ADVANCED ANALYTICS (A3): COMPANY OVERVIEW
             12.2.5 DOVE QUALITY SOLUTIONS
                       TABLE 319 DOVE QUALITY SOLUTIONS: COMPANY OVERVIEW
             12.2.6 FIRMA CLINICAL RESEARCH
                       TABLE 320 FIRMA CLINICAL RESEARCH: COMPANY OVERVIEW
             12.2.7 CELERION
                       TABLE 321 CELERION: COMPANY OVERVIEW
             12.2.8 NOVOTECH HEALTH HOLDINGS
                       TABLE 322 NOVOTECH HEALTH HOLDINGS: COMPANY OVERVIEW
             12.2.9 GENETICIST INC.
                       TABLE 323 GENETICIST INC.: COMPANY OVERVIEW
             12.2.10 LINICAL AMERICAS
                       TABLE 324 LINICAL AMERICAS: COMPANY OVERVIEW

13 APPENDIX (Page No. - 310)
     13.1 DISCUSSION GUIDE
     13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     13.3 AVAILABLE CUSTOMIZATIONS
     13.4 RELATED REPORT
     13.5 AUTHOR DETAILS

This technical, market-oriented, and financial study of the global clinical trials market involved extensive secondary sources, directories, and databases to identify and collect relevant information. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess market growth prospects. The global size of the clinical trials market (estimated through various research approaches) was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Data

The secondary sources referred to for this research study include publications from government sources, such as the Association of Clinical Research Organization (ACRO), Clinical Research Society (CRS), Clinical Research Association of Canada (CRAC), Association of International Contract Research Organizations (AICROS), Clinical and Contract Research Association (CCRA), American Association of Pharmaceutical Scientists (AAPS), Eurostat, Food and Drug Administration (FDA), Pharmaceutical Research and Manufacturers of America (PhRMA), Japan CRO Association, Chinese Association for Laboratory Animal Sciences (CALAS), and Indian Society for Clinical Research. Secondary sources include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global clinical trials market, which was validated through primary research.

Primary Data

Extensive primary research was conducted after acquiring basic knowledge about the global clinical trials market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (personnel from pharmaceutical & biopharmaceutical companies, medical device companies, and academic institutes) and supply-side (C-level and D-level executives, product managers, and marketing and sales managers of key manufacturers, distributors, and channel partners, among others, from tier 1 and tier 2 companies engaged in offering services) across five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Approximately 40% of primary interviews were conducted with supply-side representatives, while demand-side participants accounted for the remaining. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

Primary research was used in this report to:

  • Validate the market segmentation defined through a product and service portfolio assessment of the leading players in the clinical trials market
  • Understand key industry trends and issues defining the strategic growth objectives of market players
  • Gather both demand- and supply-side validation of the key factors affecting the market growth (such as market drivers, challenges, and opportunities)
  • Validate assumptions for the market sizing and forecasting model used for this study
  • Understand the market position of leading players in the clinical trials market and their market shares/rankings

Clinical Trials Market  Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Data Triangulation

After arriving at the market size from the market size estimation process explained above, the total clinical trials market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Report Objectives

  • To define, describe, and forecast the global clinical trials market based on phase, service type, therapy area, application, and region.
  • To provide detailed information regarding the major factors influencing the market growth (drivers, opportunities, and industry-specific challenges) along with the current trends
  • To strategically analyze micromarkets with respect to their individual growth trends, future prospects, and contributions to the total clinical trials market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the revenue of market segments with respect to five major regions:
    North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile key players and comprehensively analyze their market shares and core competencies
  • To track and analyze competitive developments in the clinical trials market, such as service launches, agreements, partnerships, collaborations, mergers & acquisitions, and research & development activities.

Available Customizations:

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Geographical Analysis

  • Further breakdown of the rest of Europe clinical trials market, by country
  • Further breakdown of the rest of Asia Pacific clinical trials market, by country
  • Further breakdown of the Latin American and Middle Eastern & African clinical trials market, by country

Company Information

Detailed analysis and profiling of additional market players (up to 5) inclusive of:

  • Business Overview
  • Financial Information
  • Product Offered
  • Developments (Last three years)
Report Code
PH 1622
Published ON
Feb, 2022
Choose License Type
BUY NOW
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Clinical Trials Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved